Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Atrial Fibrillation | Treatment Algorithms | Claims Data Analysis | US | 2014
For the estimated 4.6 million people in the United States who suffer from atrial fibrillation (AF), several treatment approaches and a wide range of pharmacological treatment options are available…
Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome (Novel Oral Anticoagulants in LATAM – Evolving Treatments ) | Physician & Payer Forum | Brazil and Mexico | 2014
The launch of novel oral anticoagulants (NOACs), such as Bayer/Janssen’s Xarelto, Bristol-Myers Squibb/Pfizer’s Eliquis/Elicuis, and Boehringer Ingelheim’s Pradaxa/Pradaxar, in Brazil and…
Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome (Novel Oral Anticoagulants – Evolving Treatments ) | Physician & Payer Forum | China | 2014
Warfarin has been the mainstay of anticoagulation therapy for the past several decades, but difficulties associated with its use and the clinical management of patients have prompted the…
The Impact of ACOs on Prescribing for Acute Coronary Syndrome and Atrial Fibrillation: Actionable Insights from U.S. Payers and Prescribers | Physician & Payer Forum | US | 2014
Accountable care organizations (ACOs), in which providers are held accountable for the costs of treating a payer’s patent population, will become more the rule than the exception in a year, as…